Sandu Pharmaceuticals Limited has filed its quarterly compliance statement with the Bombay Stock Exchange (BSE) confirming no deviation in the utilization of funds raised through preferential issue for the quarter ended December 31, 2025. The statement, submitted on February 6, 2026, covers three separate tranches of fund raising conducted between 2021 and 2022.

Fund Utilization Across Three Tranches

The company reported complete adherence to original fund utilization objectives across all three tranches of preferential issue. The comprehensive statement demonstrates systematic fund deployment for intended business purposes.

Original Fund Utilization Objectives

The proceeds from all three tranches were designated for specific business enhancement activities. The company allocated funds toward revamping existing capital machinery, developing marketing infrastructure, and civil work required for major plant and machinery. Additional objectives included:

• Purchase of new and additional plant and machinery
• Working capital requirements
• Investment in new technologies
• General business enhancement purposes

Regulatory Compliance and Oversight

The statement was prepared pursuant to Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and SEBI Circular CIR/CFD/CMD1/162/2019 dated December 24, 2019. The Audit Committee reviewed the statement and noted approval of the fund utilization pattern across all tranches.

Outstanding Fund Balance

For the third tranche, the company maintains unutilized funds in an escrow account as of December 31, 2025. A fixed deposit has been created in the name of the company with Bank of Baroda to facilitate fund utilization as and when required for approved objectives.

The statement was signed by Pratika Mhambray, Company Secretary & Compliance Officer, and Umesh Sandu, Managing Director (DIN: 01132141), confirming the accuracy of the reported fund utilization status.

Sandu Pharmaceuticals Limited has announced that its Board of Directors will convene on February 06, 2026, to review and approve the company's quarterly financial performance. The meeting represents a key corporate governance milestone as the company prepares to disclose its financial results for the third quarter of fiscal year 2026.

Board Meeting Details

The board meeting is scheduled with specific parameters that reflect the company's commitment to regulatory compliance and transparency.

Financial Results Review

The primary agenda item focuses on the approval of standalone unaudited financial results for the quarter ended December 31, 2025. This quarterly review will provide stakeholders with insights into the company's operational performance during the third quarter of fiscal year 2026. The board will also consider any additional matters that may arise with the chairman's permission.

Regulatory Compliance Measures

In adherence to SEBI regulations regarding insider trading prevention, Sandu Pharmaceuticals has implemented comprehensive compliance measures. The company has established a trading window closure that affects multiple stakeholder categories.

Corporate Communication

The formal communication was issued under reference number SPL/Corp.Sec/2025-26/24 dated January 24, 2026, and addressed to the Bombay Stock Exchange Limited. Company Secretary and Compliance Officer Pratika Mhambray signed the notification, ensuring proper documentation and regulatory adherence. The company operates under scrip code 524703 on the exchange and maintains its corporate office at the specified Mumbai location.

This scheduled board meeting demonstrates Sandu Pharmaceuticals' commitment to maintaining transparent communication with stakeholders and adhering to established corporate governance practices while ensuring compliance with securities market regulations.